Smith & Nephew (LON:SN) Hits New 52-Week High – Here’s What Happened

Smith & Nephew plc (LON:SN) shares reached a new 52-week high on Wednesday . The company traded as high as GBX 1,258.50 and last traded at GBX 1,255, with a volume of 2359560 shares trading hands. The stock had previously closed at GBX 1,256.

Analysts Set New Price Targets

Several analysts have recently weighed in on SN shares. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Smith & Nephew in a research report on Friday, November 7th. Panmure Gordon reaffirmed a “hold” rating and issued a GBX 1,200 price target on shares of Smith & Nephew in a report on Tuesday, December 9th. Royal Bank Of Canada lowered shares of Smith & Nephew to a “sector perform” rating and decreased their price objective for the stock from GBX 1,700 to GBX 1,350 in a report on Wednesday, December 17th. Finally, Citigroup upped their target price on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research note on Friday, October 31st. Two investment analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of GBX 1,381.33.

Smith & Nephew Price Performance

The company has a quick ratio of 0.84, a current ratio of 2.51 and a debt-to-equity ratio of 70.22. The stock’s 50-day moving average price is GBX 1,258.26 and its 200 day moving average price is GBX 1,273.49. The firm has a market cap of £13.76 billion, a price-to-earnings ratio of 45.18, a price-to-earnings-growth ratio of 0.46 and a beta of 0.62.

Insider Activity at Smith & Nephew

In other news, insider Deepak Nath sold 1,240 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total transaction of £15,586.80. Corporate insiders own 0.19% of the company’s stock.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.